Q-omics provides the consensus-scored ARID4B profile across patient tissues and cancer cell-line models. ARID4B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARID4B is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ARID4B protein abundance shows 23,693 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where ARID4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARID4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARID4B survival associations across molecular data types. ARID4B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARID4B RNA expression–survival associations across cancer types. High ARID4B expression shows unfavorable associations in ACC, KIRP and UVM, but favorable associations in SKCM, KIRC and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARID4B RNA expression.
This table summarizes ARID4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARID4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARID4B shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, BRCA and STAD. The HNSC box plot shows higher ARID4B RNA expression in tumor versus normal tissue (log2 FC = +0.749, t-test p < 0.001).
This table shows molecular features associated with ARID4B in patient tissues and cancer cell lines. In patient samples, ARID4B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARID4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
